US Patent

US10086011 — Combination formulation of two antiviral compounds

Method of Use · Assigned to Gilead Pharmasset LLC · Expires 2034-01-30 · 8y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent discloses pharmaceutical compositions containing Compound I and substantially crystalline sofosbuvir, along with methods of using these compositions.

USPTO Abstract

Disclosed are pharmaceutical compositions comprising Compound I, having the formula: and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1470`	—
`U-1470`	—

Patent Metadata

Patent number: US10086011
Jurisdiction: US
Classification: Method of Use
Expires: 2034-01-30
Drug substance claim: No
Drug product claim: No
Assignee: Gilead Pharmasset LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.